Synovium in the pathophysiology of osteoarthritis

Therapy

Volumn 7, Issue 6, 2010, Pages 661-668

  Monemdjou, Roxana ^a   Fahmi, Hassan ^a   Kapoor, Mohit ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

cartilage; cytokines; IL 1 ; matrix metalloproteases; osteoarthritis; synovium

Indexed keywords

ADALIMUMAB; AGGRECANASE 2; COLLAGENASE 3; GELATINASE A; GELATINASE B; INFLIXIMAB; INTERLEUKIN 15; INTERLEUKIN 1BETA; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AGING; ARTICULAR CARTILAGE; CARTILAGE DEGENERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; EXTRACELLULAR MATRIX; GENE THERAPY; HAND OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; NONHUMAN; OSTEOARTHRITIS; OSTEOPHYTE; PATHOPHYSIOLOGY; REVIEW; SYNOVITIS; UNSPECIFIED SIDE EFFECT;

EID: 78649377502     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.10.72     Document Type: Review

References (40)

1. Lawrence RC, Felson DT, Helmick CG et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58(1), 26-35 (2008).
2. Martel-Pelletier J, Lajeunesse D, Pelletier JP: Etiopathogenesis of osteoarthritis. In: Arthritis and Allied Conditions. A Textbook of Rheumatology (15th Edition). Koopman WJ, Moreland LW (Eds). Lippincott, Williams & Wilkins, Baltimore, MD, USA (2005).
3. Martel-Pelletier J, Pelletier JP: Is osteoarthritis a disease involving only cartilage or other articular tissues? Eklem Hastalik Cerrahisi 21(1), 2-14 (2010).
4. van Lent PL, Blom AB, van der Kraan P et al. Crucial role of synovial lining macrophages in the promotion of transforming growth factor p-mediated osteophyte formation. Arthritis Rheum. 50(1), 103-111 (2004).
5. Blom AB, van Lent PL, Holthuysen AE et al. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. Osteoarthr. Cartil. 12(8), 627-635 (2004).
6. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB: Differential effects of local application of BMP-2 or TGF-pl on both articular cartilage composition and osteophyte formation. Osteoarthr. Cartil. 6(5), 306-317 (1998).
7. Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB: Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor p/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum. 48(12), 3442-3451 (2003).
8. Bakker AC, van de Loo FA, van Beuningen HM et al.: Overexpression of active TGF-β-1 in the murine knee joint: evidence for synovial-layer- dependent chondro-osteophyte formation. Osteoarthr. Cartil. 9(2), 128-136(2001).
9. Krasnokutsky S, Attur M, Palmer G, Samuels J, Abramson SB: Current concepts in the pathogenesis of osteoarthritis. Osteoarthr. Cartil. l6(Suppl. 3), S1-S3 (2008).
10. Ayral X, Dougados M, Listrat V, Bonvarlet JP, Simonnet J, Amor B: Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. J. Rheumatol. 23(4), 698-706 (1996).
11. Kristoffersen H, Torp-Pedersen S, Terslev L et al.: Indications of inflammation visualized by ultrasound in osteoarthritis of the knee. Acta Radiol. 47(3), 281-286 (2006).
12. Holderbaum D, Haqqi TM, Moskowitz RW: Genetics and osteoarthritis: exposing the iceberg. Arthritis Rheum. 42(3), 397-405 (1999).
13. Benito MJ, Veale DJ, Fitz Gerald O, van den Berg WB, Bresnihan B: Synovial tissue inflammation in early and late osteoarthritis. Ann. Rheum. Dis. 64(9), 1263-1267(2005).
14. Cameron ML, Fu FH, Paessler HH, Schneider M, Evans CH: Synovial fluid cytokine concentrations as possible prognostic indicators in the ACL-deficient knee. Knee Surg Sports Traumatol. Arthrosc. 2(1), 38-44 (1994).
15. Scanzello CR, Umoh E, Pessler F et al.: Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthr. Cartil. 17(8), 1040-1048 (2009).
16. Martel-Pelletier J, Lajeunesse D, Pelletier J-P: Etiopathogenesis of osteoarthritis. In: Arthritis and Allied Conditions. A Textbook of Rheumatology. (15th Edition). Koopman WJ, Moreland LW (Eds). Lippincott, Williams & Wilkins,MD, USA (2005).
17. Pelletier JP, Martel-Pelletier J, Abramson SB: Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 44(6), 1237-1247(2001).
18. Loeser RF: Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum. 54(5), 1357-1360(2006).
19. Goldring SR, Goldring MB: The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin. Orthop. Relat. Res. 427(Suppl.), S27-S36 (2004).
20. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB: Protection from interleukin 1 induced destruction of articular cartilage by transforming growth factor p: studies in anatomically intact cartilage in vitro and in vivo. Ann. Rheum. Dis. 52(3), 185-191 (1993).
21. Schlaak JF, Pfers I, Meyer zum Buschenfelde KH, Marker-Hermann E: Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin. Exp. Rheumatol. 14(2), 155-162(1996).
22. Lafyatis R, Thompson NL, Remmers EF et al.: Transforming growth factor-p production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. J. Immunol. 143(4), 1142-1148(1989).
23. Chubinskaya S, Kuettner KE: Regulation of osteogenic proteins by chondrocytes. Int. J. Biochem. Cell Biol. 35(9), 1323-1340 (2003).
24. Sakkas LI, Scanzello C, Johanson N et al.: T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis. Clin. Diagn. Lab. Immunol. 5(4), 430-437 (1998).
25. Ishii H, Tanaka H, Katoh K, Nakamura H, Nagashima M, Yoshino S: Characterization of infiltrating T cells and Thl/Th2-type cytokines in the synovium of patients with osteoarthritis. Osteoarthr. Cartil. 10(4), 277-281 (2002).
26. Marini S, Fasciglione GF, Monteleone G, Maiotti M, Tarantino U, Coletta M: A correlation between knee cartilage degradation observed by arthroscopy and synovial proteinases activities. Clin. Biochem. 36(4), 295-304 (2003).
27. Barksby HE, Milner JM, Patterson AM et al.: Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum. 54(10), 3244-3253 (2006).
28. Masuhara K, Nakai T, Yamaguchi K, Yamasaki S, Sasaguri Y: Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum. 46(10), 2625-2631 (2002).
29. Tchetverikov I, Lohmander LS, Verzijl N et al.: MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann. Rheum. Dis. 64(5), 694-698 (2005).
30. Hsieh YS, Yang SF, Chu SC et al.: Expression changes of gelatinases in human osteoarthrhic knees and arthroscopic debridement. Arthroscopy 20(5), 482-488 (2004).
31. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ: Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273(5275), 613-622 (1996).
32. -/- mice have less subchondral bone changes after induction of osteoarthritis through surgical instability: implications for a link between cartilage and subchondral bone changes. Osteoarthr. Cartil. 17(5), 636-645 (2009).
33. Glasson SS, Askew R, Sheppard B et al.: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434(7033), 644-648 (2005).
34. Vankemmelbeke MN, Holen I, Wilson AG et al.: Expression and activity of ADAMTS-5 in synovium. Eur. J. Biochem. 268(5), 1259-1268 (2001).
35. Caron JP, Fernandes JC, Martel-Pelletier J et al.: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum. 39(9), 1535-1544 (1996).
36. Fernandes J, Tardif G, Martel-Pelletier J et al.: In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthrkic rabbit knee joints: prevention of osteoarthritis progression. Am. J. Pathol. 154(4), 1159-1169 (1999).
37. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P: Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol. 32(7), 1317-1323 (2005).
38. Chevalier X, Goupille P, Beaulieu AD et al: Intraarticular injection ofanakinrain osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 61(3), 344-352 (2009).
39. Grunke M, Schulze-Koops H: Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann. Rheum. Dis. 65(4), 555-556 (2006).
40. Krzeski P, Buckland-Wright C, Balint G et al.: Development of musculoskelet al toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study Arthritis Res. Ther. 9(5), R109 (2007).